Skip to main content
BMC Musculoskeletal Disorders logoLink to BMC Musculoskeletal Disorders
. 2023 Mar 6;24:169. doi: 10.1186/s12891-023-06262-8

Correction: Inhibition of SMAD3 effectively reduces ADAMTS‑5 expression in the early stages of osteoarthritis

Wei Xiang 1,#, Chao Wang 2,3,#, Zhoujun Zhu 4,#, Dui Wang 3, Zhenyu Qiu 3, Weishan Wang 2,3,
PMCID: PMC9987138  PMID: 36879213

Correction: BMC Musculoskelet Disorders 24, 130 (2023)

10.1186/s12891-022-05949-8

Following publication of the original article [1], the authors identified an error in the first author’s affiliation. Dr. Wei Xiang’s affiliation should only be “1Renmin Hospital of Zhijiang, Yichang, Hubei, China”.

The original article [1] has been updated.

Footnotes

The online version of the original article can be found at 10.1186/s12891-022-05949-8.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Wei Xiang, Chao Wang and Zhoujun Zhu contributed equally to this work.

References

  • 1.Xiang W, Wang C, Zhu Z, et al. Inhibition of SMAD3 effectively reduces ADAMTS-5 expression in the early stages of osteoarthritis. BMC Musculoskelet Disord. 2023;24:130. doi: 10.1186/s12891-022-05949-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMC Musculoskeletal Disorders are provided here courtesy of BMC

RESOURCES